Megakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connection

A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2

(2012) Kai B. Kaufmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice

(2012) Giovanni Barosi et al.   Current Hematologic Malignancy Reports

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

(2011) P. Guglielmelli et al.   BLOOD

New mutations and pathogenesis of myeloproliferative neoplasms

(2011) W. Vainchenker et al.   BLOOD

Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane

(2011) M. Bignon et al.   BLOOD

The HIF-1-Inducible Lysyl Oxidase Activates HIF-1 via the Akt Pathway in a Positive Regulation Loop and Synergizes with HIF-1 in Promoting Tumor Cell Growth

(2011) F. Pez et al.   CANCER RESEARCH

Control of Megakaryocyte Expansion and Bone Marrow Fibrosis by Lysyl Oxidase

(2011) Alexia Eliades et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms

(2011) Chor Sang Chim et al.   Journal of Translational Medicine

Management of Myelofibrosis

(2011) A. M. Vannucchi   Hematology-American Society of Hematology Education Program

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2

(2010) W. Wang et al.   BLOOD

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease

(2010) H. Akada et al.   BLOOD

Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells

(2010) Ann Mullally et al.   CANCER CELL

Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis

(2010) Sameer A. Parikh et al.   Clinical Lymphoma Myeloma & Leukemia

The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera

(2010) Khadija Abdulkarim et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria

(2010) Martha Wadleigh et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

(2010) Vivian Barry-Hamilton et al.   NATURE MEDICINE

Megakaryopoiesis

(2010) Amy E. Geddis   SEMINARS IN HEMATOLOGY

Lysyl oxidase: a potential target for cancer therapy

(2010) Siddikuzzaman et al.   INFLAMMOPHARMACOLOGY

Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim

(2009) D. J. Kuter et al.   BLOOD

Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome

(2009) S. Malinge et al.   BLOOD

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

(2009) F. P. S. Santos et al.   BLOOD

Lysyl Oxidase (Lox) Gene Deficiency Affects Osteoblastic Phenotype

(2009) N. Pischon et al.   CALCIFIED TISSUE INTERNATIONAL

Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Reticulin Accumulation in Essential Thrombocythemia: Prognostic Significance and Relationship to Therapy

(2009) Peter J. Campbell et al.   JOURNAL OF CLINICAL ONCOLOGY

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

(2009) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

The Lysyl Oxidase Inhibitor, β-Aminopropionitrile, Diminishes the Metastatic Colonization Potential of Circulating Breast Cancer Cells

(2009) Alla Bondareva et al.   PLoS One

Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis

(2009) Lilian Varricchio et al.   Expert Review of Hematology

Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines

(2008) Oliver Bock et al.   AMERICAN JOURNAL OF PATHOLOGY

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort

(2008) P. A. Beer et al.   BLOOD

Activating mutations in human acute megakaryoblastic leukemia

(2008) S. Malinge et al.   BLOOD

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

(2008) F. Passamonti et al.   BLOOD

Lysyl Oxidase Oxidizes Cell Membrane Proteins and Enhances the Chemotactic Response of Vascular Smooth Muscle Cells

(2008) Héctor A. Lucero et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Proteomics of the TRAP-induced platelet releasate

(2008) Sander R. Piersma et al.   Journal of Proteomics

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

(2008) A M Vannucchi et al.   LEUKEMIA

From Palliation to Epigenetic Therapy in Myelofibrosis

(2008) A. Rambaldi et al.   Hematology-American Society of Hematology Education Program

Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome

(2007) G. Kirsammer et al.   BLOOD

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

(2007) R. Tiedt et al.   BLOOD